A double-blind, randomized, multi-center, flexible dose study evaluating the efficacy and safety of SPD503 (guanfacine hydrochloride) in children aged 6-12 with symptoms of oppositionality and a diagnosis of attention deficit/hyperactivity disorder.

Trial Profile

A double-blind, randomized, multi-center, flexible dose study evaluating the efficacy and safety of SPD503 (guanfacine hydrochloride) in children aged 6-12 with symptoms of oppositionality and a diagnosis of attention deficit/hyperactivity disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Guanfacine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 01 Sep 2010 Results have been published (CNS Drugs 24: No. 9).
    • 26 May 2010 Results evaluating the effect of treatment on parental stress presented at the 163rd Annual Meeting of the American Psychiatric Association.
    • 17 Dec 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top